Shots:

• AstraZeneca has submitted a request to the US FDA seeking EUA for its AZD7442 to treatprophylaxis of symptomatic COVID-19. If EUA is granted- AZD7442 will be the first LAAB for COVID-19 prevention
• The filing is based on the safety and efficacy data from the P-III PROVENT & STORM CHASER trials along with the P-I trial. The P-III trials showed a 77% reduction in risk of developing symptomatic COVID-19 with a long-acting Ab combination
• In preliminary in vitro data- AZD7442 demonstrated a broad anti-COVID activity & neutralized newly emergent SARS-CoV-2 viral variants. The company is in discussion with the US Government & other governments globally for the supply agreements of AZD7442

Ref: AstraZeneca | Image: The Scientist Magazine